Vorozole: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|An article about the nonsteroidal aromatase inhibitor Vorozole}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Vorozole.svg | |||
| image2 = <!-- Another image if available --> | |||
}} | |||
'''Vorozole''' is a nonsteroidal [[aromatase inhibitor]] that is used in the treatment of [[breast cancer]]. It functions by inhibiting the enzyme aromatase, which is responsible for the conversion of [[androgens]] into [[estrogens]]. This reduction in estrogen levels is beneficial in treating estrogen receptor-positive breast cancer. | |||
== | ==Mechanism of Action== | ||
Vorozole | Vorozole works by binding to the aromatase enzyme, thereby preventing it from converting androgens such as [[testosterone]] and [[androstenedione]] into estrogens. This leads to a decrease in circulating estrogen levels, which can slow or halt the growth of estrogen-dependent tumors. | ||
== | ==Clinical Use== | ||
Vorozole is primarily used in the treatment of postmenopausal women with hormone receptor-positive breast cancer. It is part of a class of drugs known as aromatase inhibitors, which are often used as a first-line treatment or after [[tamoxifen]] therapy. | |||
== | ==Side Effects== | ||
Vorozole | Common side effects of Vorozole include hot flashes, joint pain, and fatigue. As with other aromatase inhibitors, there is also a risk of osteoporosis due to decreased estrogen levels, which can lead to bone density loss. | ||
== | ==Pharmacokinetics== | ||
Vorozole is administered orally and is well absorbed from the gastrointestinal tract. It has a half-life that allows for once-daily dosing. The drug is metabolized in the liver and excreted primarily in the urine. | |||
==History== | |||
Vorozole was developed as part of a class of drugs aimed at reducing estrogen levels in the body. It was one of the early nonsteroidal aromatase inhibitors to be studied for its efficacy in breast cancer treatment. | |||
==Related pages== | |||
* [[Aromatase inhibitor]] | * [[Aromatase inhibitor]] | ||
* [[Breast cancer]] | * [[Breast cancer]] | ||
* [[ | * [[Estrogen receptor]] | ||
* [[Tamoxifen]] | |||
[[ | |||
[[Category:Antineoplastic drugs]] | |||
[[Category:Aromatase inhibitors]] | |||
[[Category:Breast cancer treatments]] | |||
Revision as of 03:51, 13 February 2025
An article about the nonsteroidal aromatase inhibitor Vorozole
| Vorozole | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Vorozole is a nonsteroidal aromatase inhibitor that is used in the treatment of breast cancer. It functions by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens into estrogens. This reduction in estrogen levels is beneficial in treating estrogen receptor-positive breast cancer.
Mechanism of Action
Vorozole works by binding to the aromatase enzyme, thereby preventing it from converting androgens such as testosterone and androstenedione into estrogens. This leads to a decrease in circulating estrogen levels, which can slow or halt the growth of estrogen-dependent tumors.
Clinical Use
Vorozole is primarily used in the treatment of postmenopausal women with hormone receptor-positive breast cancer. It is part of a class of drugs known as aromatase inhibitors, which are often used as a first-line treatment or after tamoxifen therapy.
Side Effects
Common side effects of Vorozole include hot flashes, joint pain, and fatigue. As with other aromatase inhibitors, there is also a risk of osteoporosis due to decreased estrogen levels, which can lead to bone density loss.
Pharmacokinetics
Vorozole is administered orally and is well absorbed from the gastrointestinal tract. It has a half-life that allows for once-daily dosing. The drug is metabolized in the liver and excreted primarily in the urine.
History
Vorozole was developed as part of a class of drugs aimed at reducing estrogen levels in the body. It was one of the early nonsteroidal aromatase inhibitors to be studied for its efficacy in breast cancer treatment.
